Why did Caplin Point Laboratories (CAPLIPOINT) stock move recently?

On 7/27/2026, Caplin Point Laboratories moved +6.3% — No specific company news or filing explains the move; Caplin Point rose with broader market or sector momentum. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Caplin Point Laboratories (CAPLIPOINT) overvalued or fairly valued?

MarketChacha shows Caplin Point Laboratories's valuation in context — a forward P/E of about 20.4, a price-to-book of about 4.9 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Caplin Point Laboratories's revenue?

Caplin Point Laboratories reported revenue of ₹2,187 Cr for FY2026, with net profit of ₹641 Cr, per official filings.

What is the share price of Caplin Point Laboratories (CAPLIPOINT)?

Caplin Point Laboratories last traded at ₹2,258.80 (-1.8% on the day), as of 10/19/2026 — a delayed quote shown for education, not investment advice.

Caplin Point Laboratories

CAPLIPOINT · NSE · Pharma · India

Snapshot

TickerCAPLIPOINT

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

Employees4,199

HeadquartersChennai, India

Websitewww.caplinpoint.net

Filings tracked5

About Caplin Point Laboratories

Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel, capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag, inhalers, and sprays and IV infusion. It also provides dry and syrups, lyophilized vials, prefilled syringes, emulsion injection, ophthalmic droppers, sachets, liquid injectables, topicals, pre-filled syringes, and pre-mix bags. Caplin Point Laboratories Limited was incorporated in 1990 and is headquartered in Chennai, India.

Who owns it

Promoters73.4%
Institutions5.7%
Public & other20.9%

49 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend25.7% → 29.3%

Margin has expanded by about 3.7 points — the business is getting more profitable.

Growth qualityrev 14% · PAT 19%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next fiscal year

Rev ₹2,834 Cr · EPS 110.70

Est. earnings growth +15.8%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 4

Revenue (FY2026)

₹2,187 Cr

Net margin

29.3%

Revenue CAGR (3y)

+14.2%

Profit CAGR (3y)

+19.4%

Net profit (FY2026)

₹641 Cr

Ask MarketChacha about CAPLIPOINT

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jul 27, 2026
No specific company news or filing explains the move; Caplin Point rose with broader market or sector momentum.
· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹2,187 Cr	₹641 Cr	29.3%
FY2025	₹1,937 Cr	₹536 Cr	27.7%
FY2024	₹1,694 Cr	₹457 Cr	27.0%
FY2023	₹1,467 Cr	₹376 Cr	25.7%

Quarterly

Period	Revenue	Net profit	Net margin
Q3 FY26	₹543 Cr	₹164 Cr	30.2%
Q2 FY26	₹534 Cr	₹154 Cr	28.9%
Q1 FY26	₹510 Cr	₹153 Cr	29.9%
Q4 FY25	₹502 Cr	₹143 Cr	28.4%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

Filings & announcements

2026

Business Responsibility and Sustainability Reporting (BRSR)
Business Responsibility and Sustainability Report for the Financial Year 2025-26
BSE9/3/2026
Notice Of The 35Th Annual General Meeting
Notice of the 35th Annual General Meeting of the Company
BSE9/3/2026material
Reg. 34 (1) Annual Report.
Annual Report for the Financial Year 2025-26
BSE9/3/2026
General Updates
Completion of Unannounced USFDA Inspection at the facility of Caplin Steriles Limited (Company''s subsidiary)
BSE8/21/2026
Earnings Call Transcript
Transcript for Earnings call- Q1- FY 2026-27
BSE8/19/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.